In Vivo is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Can't Say No: Pharma's Addiction to Shareholder Payouts

Executive Summary

Having created a shareholder addiction to cash payments, companies are now going to have to make the unpleasant choice between pleasing investors in the short term and building their businesses over the next decade. IN VIVO examines pipeline confidence, patent expirations, and cash flow woes to make some forecasts about the industry's financial health, as well as looking inside the strategies that Big Pharma is currently pursuing.
Advertisement

Related Content

Best of the Blog February 2010
Best of the Blog February 2010
Pharma Share Buybacks Could Draw Policymakers’ Scrutiny, Professor Warns
Pharmaceutical/Biotechnology Deal Statistics Quarterly, Q1 2008
Pharmaceutical/Biotechnology Deal Statistics Quarterly, Q1 2008
The Unsung Vytorin Victim: Primary-Care Marketing
The Unsung Vytorin Victim: Primary-Care Marketing
Are Share Buybacks a Wise Investment for Biopharma

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

IV003078

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel